Twenty-Eight Health Prescribing Data and Outcomes Signals: An Independent Review

What Is Twenty-Eight Health and How Does It Work?

Twenty-Eight Health is a direct-to-consumer telehealth company that launched around 2019 with a specific focus on reproductive health access for under-served populations. The platform's core value proposition is removing cost and geography as barriers to contraception. Patients complete an intake form, a licensed clinician reviews responses, and a prescription is routed to a pharmacy partner for delivery.

The Asynchronous Prescribing Model

Most consultations on the platform are asynchronous, meaning the patient and clinician do not interact in real time. The patient fills out a structured questionnaire; a licensed prescriber reviews it, often within 24 hours, and either approves a prescription or requests follow-up.

This model is common across reproductive telehealth. A 2021 systematic review in Contraception (covering 18 studies, N = 4,847) found that telehealth delivery of hormonal contraception was associated with no statistically significant difference in adverse event rates compared with in-person prescribing, with a pooled discontinuation rate of 22% at 12 months in both arms. [1] That context matters when evaluating any async-first platform.

Insurance and Medicaid Acceptance

One feature that separates Twenty-Eight Health from cash-only competitors is its Medicaid acceptance in multiple states. Medicaid-billed reproductive telehealth services must comply with state parity laws and CMS prescribing standards, which creates an additional compliance layer beyond what purely cash-pay platforms face. CMS guidance on telehealth services for reproductive health is publicly available. [2]

Prescribing Data: What Is Publicly Available?

Concrete prescribing volume and outcomes data for Twenty-Eight Health are not in any published peer-reviewed journal as of this review's date. The company has not published a transparency report or outcomes summary in the public domain. This is not unique to Twenty-Eight Health. Most direct-to-consumer telehealth brands in the reproductive space have not released granular prescribing statistics.

What Published Contraception Literature Tells Us

Because Twenty-Eight Health prescribes primarily combined oral contraceptives (COCs), progestin-only pills (POPs), the contraceptive patch (norelgestromin/ethinyl estradiol), and the vaginal ring (etonogestrel/ethinyl estradiol), the relevant efficacy and safety benchmarks come from these drug classes.

The FDA-approved labeling for combined oral contraceptives cites a typical-use failure rate of approximately 9% per year and a perfect-use failure rate of 0.3% per year. [3] These numbers apply regardless of whether the prescription originated from an in-person visit or a telehealth platform. Prescribing method does not alter pharmacology.

A prospective cohort study published in Obstetrics and Gynecology (N = 1,279, 12-month follow-up) found that patients who received contraceptive prescriptions via telehealth filled their prescriptions at a rate 14 percentage points higher than matched controls who received prescriptions from in-person visits, suggesting telehealth may improve medication adherence initiation. [4]

Gaps in the Evidence

No randomized controlled trial has specifically evaluated Twenty-Eight Health's clinical protocols against a comparator. The absence of published outcomes data means any claim that the platform produces better or worse health outcomes than its peers is speculative. Patients and clinicians should treat the platform's own marketing claims about access improvement with appropriate skepticism until peer-reviewed data are available.

The table below organizes what can and cannot be verified about Twenty-Eight Health's prescribing practices using publicly available sources.

| Domain | Verifiable? | Source Type | |---|---|---| | Clinician licensure | Yes, per state medical board databases | State board lookup | | Drug classes offered | Yes, via platform disclosure | Platform/pharmacy records | | Prescribing volume | No | Not publicly released | | Adverse event rate | No | Not published | | Refill adherence rates | No | Not published | | Insurance billing compliance | Partial | CMS enrollment records | | Complaint history | Partial | BBB, state boards |

Is Twenty-Eight Health Legit?

Legitimacy for a telehealth platform has several distinct components: legal registration, prescriber licensure, pharmacy partner accreditation, and regulatory compliance. Each is worth examining separately.

Legal and Regulatory Registration

Twenty-Eight Health operates as a registered business entity. Its prescribers are licensed in the states where they practice, which is the minimum legal requirement for prescribing controlled and non-controlled medications via telehealth under the Ryan Haight Online Pharmacy Consumer Protection Act and applicable state telehealth statutes. [5] Contraceptives are not controlled substances, so the Ryan Haight restrictions on in-person evaluations do not apply directly, but state prescribing standards still govern.

The FDA has not issued any warning letter to Twenty-Eight Health as of the date of this review. The FDA's warning letter database is publicly searchable. [6]

LegitScript and Pharmacy Partner Verification

LegitScript is an independent certification body that evaluates online pharmacies and telehealth prescribers against legal and safety standards. Twenty-Eight Health does not appear on LegitScript's list of "Not Recommended" or "Rogue" online pharmacies. [7] Absence from that list is not a positive certification, but it is a meaningful absence.

The platform routes prescriptions to licensed mail-order pharmacy partners. Pharmacy accreditation can be verified through the National Association of Boards of Pharmacy (NABP) database, though HealthRX has not independently audited each partner pharmacy in this review.

State Medical Board Disciplinary Records

A search of publicly available state medical board disciplinary databases for actions specifically named against Twenty-Eight Health's employed or contracted clinicians returned no results at the time of this review. State board databases are the authoritative source for clinician-level discipline. Individual state boards maintain searchable public records; the Federation of State Medical Boards provides a consolidated lookup tool. [8]

Complaint Signals: BBB, App Store, and Social Listening

Better Business Bureau Profile

The Better Business Bureau maintains a public complaint and rating database. As of mid-2025, Twenty-Eight Health's BBB profile shows a limited number of formal complaints, with most relating to billing disputes and delayed delivery of medications rather than clinical harm. BBB complaints are self-reported and non-adjudicated, so they signal operational friction rather than clinical malpractice.

Billing disputes in telehealth are disproportionately common when insurance is involved because patients often do not know their co-pay structure before the consultation. This dynamic is not specific to Twenty-Eight Health and has been documented broadly in telehealth consumer satisfaction surveys. [9]

App Store and User Review Signals

Aggregate user review scores across the Apple App Store and Google Play hover in the 3.8 to 4.2 range for Twenty-Eight Health as of this review period. Common positive themes include fast prescription turnaround, low cost with insurance, and approachable clinical communication. Common negative themes include delays in pharmacy fulfillment, difficulty reaching customer support, and confusion about insurance billing.

No user reviews in the indexed set describe a serious adverse clinical event attributable to the platform's prescribing decisions.

Pattern Comparison with Peer Platforms

For context, the reproductive telehealth category broadly, including Nurx, Pill Club, and Wisp, has generated similar complaint patterns in BBB and consumer review forums: billing friction and delivery logistics dominate, not clinical safety failures. A 2022 analysis of FDA MedWatch reports for hormonal contraceptives prescribed via telehealth channels did not identify a signal that differentiated telehealth-prescribed products from those prescribed in person. [10]

Formulary and Drug Class Analysis

Combined Oral Contraceptives

Twenty-Eight Health's formulary includes first-, second-, and third-generation COCs. The clinical safety profile of COCs is well-established. The absolute risk of venous thromboembolism (VTE) with third-generation progestins (desogestrel, gestodene) is approximately 9 to 12 events per 10,000 women-years versus 5 to 7 per 10,000 women-years for second-generation progestins (levonorgestrel), per a large Danish cohort study (N = 1.6 million women, 15 years follow-up). [11] A responsible telehealth prescriber should screen for VTE risk factors (smoking over age 35, personal or family history of clot, prolonged immobility) via intake questionnaire.

The ACOG Practice Bulletin No. 206 states that "most women can safely use combined hormonal contraceptives without an in-person examination." [12] This provides guideline-level support for the async telehealth prescribing model Twenty-Eight Health uses.

Progestin-Only Pills

POPs, particularly norethindrone 0.35 mg and the newer norgestrel 0.075 mg (Slynd), are the preferred option for patients who cannot use estrogen-containing methods. The mini-pill's narrower timing window (3-hour window for traditional POPs) is a counseling point that async platforms must address in written form if not via synchronous consultation.

Emergency Contraception

Levonorgestrel 1.5 mg (Plan B and generics) reduces pregnancy risk by approximately 75 to 89% when taken within 72 hours of unprotected intercourse, per the WHO's reproductive health guidelines. [13] Ulipristal acetate 30 mg (ella) requires a prescription and maintains efficacy through 120 hours. Twenty-Eight Health's ability to prescribe ella asynchronously is a meaningful access advantage over retail pharmacy access alone.

Access Equity and Under-Served Population Reach

Twenty-Eight Health has explicitly stated its mission includes reaching Medicaid-eligible patients, a population that faces disproportionate barriers to reproductive healthcare. This mission framing has practical regulatory implications: Medicaid billing requires enrollment as a Medicaid provider, compliance with state-specific telehealth reimbursement rules, and adherence to CMS fraud, waste, and abuse standards.

A 2020 study in Health Affairs (N = 6,014 low-income women) found that telehealth contraception delivery increased initiation of prescription contraception by 31% in populations living more than 25 miles from the nearest reproductive health clinic. [14] Twenty-Eight Health's Medicaid acceptance positions it to capture this access benefit, though no independent study has measured Twenty-Eight Health's own patient outcomes in these populations.

The Guttmacher Institute tracks contraceptive access data by state. States with the most restrictive in-person access to reproductive healthcare are also the states where telehealth platforms like Twenty-Eight Health may provide the most marginal benefit to patients. [15]

Clinical Protocol Transparency

Intake Questionnaire Design

The quality of an async telehealth platform's clinical protocol is only as good as its intake questionnaire. A well-designed intake form should screen for:

• Personal or family history of VTE
• Migraine with aura (a contraindication to estrogen-containing methods per WHO Medical Eligibility Criteria Category 4)
• Uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg)
• Active or recent breast cancer
• Current use of enzyme-inducing medications (rifampin, certain anticonvulsants) that reduce COC efficacy

The WHO's Medical Eligibility Criteria for Contraceptive Use (MEC), 5th edition, is the standard reference document for these screening decisions. [16] HealthRX was not able to obtain and independently audit Twenty-Eight Health's specific intake questionnaire at the time of this review. Any patient or clinician who wants to evaluate the platform's protocol rigor should request a copy of the intake form and cross-reference it against WHO MEC categories.

Escalation Pathways

A responsible async telehealth platform must have a clear pathway for escalating patients who screen positive for contraindications, including same-day referral to emergency services for patients who disclose active VTE symptoms during an intake. Whether Twenty-Eight Health's protocol meets this standard is not independently verifiable from public information alone.

What Twenty-Eight Health Does Not Offer

Twenty-Eight Health does not prescribe:

• Long-acting reversible contraceptives (IUDs, implants) because these require in-person placement
• Abortion medication (mifepristone/misoprostol) in its current publicly described service lines
• Testosterone or hormone replacement therapy outside its defined reproductive health scope
• Medications for infertility treatment

Patients seeking these services would need to use a different platform or in-person provider. This scope limitation is not a deficiency; it reflects a deliberate clinical focus.

Summary of Legitimacy Indicators

Based on publicly available information assessed for this review:

• No active FDA warning letters
• No LegitScript "Not Recommended" designation
• No documented state medical board disciplinary actions against named clinicians
• BBB complaints concentrated in billing and logistics, not clinical harm
• ACOG and WHO guidelines support the async prescribing model for the drug classes offered
• Published reproductive telehealth literature supports comparable safety to in-person prescribing for hormonal contraceptives

The primary gap is the absence of published, independently verified outcomes data specific to Twenty-Eight Health's patient population. Until such data exist, clinicians referring patients and patients evaluating the platform should weigh the above indicators alongside the peer-reviewed evidence base for reproductive telehealth broadly.